Health
Sinopharm’s potential Covid-19 vaccine triggers antibodies in clinical trials – PharmaLive
A coronavirus vaccine candidate developed by a unit of China National Pharmaceutical Group (Sinopharm) appeared to be safe and triggered antibody-based immune responses in early and mid-stage trials, researchers said.
The shot did not cause any serious side effects, according to a paper published on Thursday in the Journal of the American Medical Association (JAMA) by scientists who are part of Sinopharm and other China-based disease control authorities and research institutes.
The results were based on data from 320 healthy adults in Phase 1 and 2 trials.
The candidate triggered robust antibody responses in inoculated people, but it remained unknown if that was sufficient to prevent COVID-19 infection, res…
-
Business15 hours agoWhy is Alphabet stock worth less than Nvidia, Microsoft, Apple, and Amazon even though it is the most profitable S&P 500 company?
-
General21 hours agoMichael Beatty, veteran current affairs journalist and animal welfare advocate, dies aged 76
-
Noosa News14 hours ago‘Sunny, benign’ school holiday weather after morning showers in parts of Queensland
-
Noosa News23 hours agoMissing man, Maroochydore – Queensland Police News